| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 01/19/2006 | WO2004028472A3 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β |
| 01/19/2006 | US20060014926 Human papillomavirus E6 and E7 polypeptides, mutant polypeptide retains 30% of the immunogenicity of an isolated polypeptide comprising human wild-type papillomavirus E6 and E7 |
| 01/19/2006 | US20060014800 Naphthalene derivatives and active compounds; interactions between the compounds and certain amino acid residues in the binding pocket of the Retinoid Nuclear receptors; interact with cellular receptors; useful in modulation of gene expression; enhanced in vitro profiles compared to known compounds |
| 01/19/2006 | US20060014784 Compounds for the treatment of metabolic disorders |
| 01/19/2006 | US20060014741 Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| 01/19/2006 | US20060013875 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 01/19/2006 | US20060013858 Fludrocortisone treatment for hearing loss |
| 01/19/2006 | US20060013800 Stable immunogenic product comprising antigenic heterocomplexes |
| 01/19/2006 | DE10392372T5 Verfahren und Vorrichtung zur Sterilisierung interner Passagen eines Zentrifugenzentratschiebers Method and apparatus for sterilizing internal passages of a Zentrifugenzentratschiebers |
| 01/19/2006 | CA2574437A1 Infusion and injection solution of levodopa |
| 01/18/2006 | EP1616182A2 Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 |
| 01/18/2006 | EP1616036A2 Method for identifying ligands specific for structural isoforms of proteins |
| 01/18/2006 | EP1616020A2 Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon |
| 01/18/2006 | EP1615995A2 Morpholino imaging and therapy via amplification targeting |
| 01/18/2006 | EP1615944A2 Antiandrogens with marginal agonist activity and methods of use |
| 01/18/2006 | EP1615932A2 Podophhyllotoxin derivatives as igf-1r inhibitors |
| 01/18/2006 | EP1615914A2 Cgrp receptor antagonists |
| 01/18/2006 | EP1615878A2 Compounds, compositions and methods |
| 01/18/2006 | EP1615875A2 Process for the preparation of gabapentin form-ii |
| 01/18/2006 | EP1615699A2 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
| 01/18/2006 | EP1615670A2 Targets for tumor growth inhibition |
| 01/18/2006 | EP1615665A2 Delivery of immune response modifier compounds |
| 01/18/2006 | EP1615633A2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 01/18/2006 | EP1615625A2 Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same |
| 01/18/2006 | EP1615623A2 Abuse-resistant oral dosage forms and method of use thereof |
| 01/18/2006 | EP1615622A2 Once daily formulations of tetracyclines |
| 01/18/2006 | EP1615621A2 Compositions for delivery of drug combinations |
| 01/18/2006 | EP1615615A2 Pharmaceutical products |
| 01/18/2006 | EP1615614A2 Optimal polyvalent vaccine for cancer |
| 01/18/2006 | EP1615613A2 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
| 01/18/2006 | EP1615612A2 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots |
| 01/18/2006 | EP1615610A2 Inhibitors of coronavirus |
| 01/18/2006 | EP1615609A2 Fullerene compositions for ameliorating dermatological conditions |
| 01/18/2006 | EP1615552A2 Sapphyrins and uses thereof |
| 01/18/2006 | EP1200115B9 Multi-dose erythropoietin formulations |
| 01/18/2006 | CN1723208A Magnesium salt of imidazole derivative |
| 01/18/2006 | CN1723196A Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/18/2006 | CN1723042A Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| 01/18/2006 | CN1723041A Stable immunogenic product comprising antigenic heterocomplexes |
| 01/18/2006 | CN1721397A Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| 01/18/2006 | CN1720994A Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 01/18/2006 | CN1237060C Quinzolone derivatives as alpha IA/B adrenergic receptor antagonists |
| 01/18/2006 | CN1236792C Brain active effect matter for prevention and treating encephalopathy and developing intelligence and its preparation method |
| 01/17/2006 | US6987175 Slurrying in aqueous solution; antibiotics |
| 01/17/2006 | US6987102 Methods to mobilize progenitor/stem cells |
| 01/17/2006 | US6987093 Single dose azithromycin |
| 01/17/2006 | CA2362394C Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
| 01/12/2006 | WO2006004633A2 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/12/2006 | WO2005048928A3 Methods for treating viral infection |
| 01/12/2006 | WO2005046619A3 Compositions and methods for modulating c-rel-dependent cytokine production |
| 01/12/2006 | WO2005041872A3 Use of peroxisome proliferator-activated receptor gamma (pparϝ) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions |
| 01/12/2006 | WO2005035731A3 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
| 01/12/2006 | WO2005027836A3 Immunogen |
| 01/12/2006 | WO2005025495A3 Methods and compositions for blocking progression of a disease state |
| 01/12/2006 | WO2005018574A3 Immunostimulatory combinations and treatments |
| 01/12/2006 | WO2005016287A3 Prkwnks as modifiers of the rac pathway and methods of use |
| 01/12/2006 | WO2005011575A3 Stabilization and ionic triggering of nitric oxide release |
| 01/12/2006 | WO2005009335A3 Live attenuated nidovirus vaccines |
| 01/12/2006 | WO2005004817A3 Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases |
| 01/12/2006 | WO2004112722A3 Microbicidal, prophylactic and therapeutic effect of ctc-96 on papilloma viruses |
| 01/12/2006 | WO2004098529A3 Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules |
| 01/12/2006 | WO2004098506A3 Treatment for age-related macular degeneration |
| 01/12/2006 | WO2004080401A3 Oral insulin therapies and protocol |
| 01/12/2006 | WO2004078130A3 Posh interacting proteins and related methods |
| 01/12/2006 | WO2004071407A3 Antisense modulation of ptp1b expression |
| 01/12/2006 | WO2004069177A3 Methods for modulating an inflammatory response |
| 01/12/2006 | WO2004062597A3 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| 01/12/2006 | WO2004032851A3 Screening and therapeutic methods relating to neurogenesis |
| 01/12/2006 | US20060009821 Method and apparatus for providing light to blood |
| 01/12/2006 | US20060009517 Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 01/12/2006 | US20060009507 LPA receptor agonists and antagonists and methods of use |
| 01/12/2006 | US20060009497 Novel tetrahydropyridine derivatives as renin inhibitors |
| 01/12/2006 | US20060009464 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; Alzheimer's disease |
| 01/12/2006 | US20060009431 Nitrosated and nitrosylated compounds, compositions and methods use |
| 01/12/2006 | US20060009416 Vitamin B6, pyridinoline, 3-hydroxypyridine, or an N-alkyl-3-hydroxypyridine; sunscreen agents |
| 01/12/2006 | US20060009375 Site-specific drug delivery |
| 01/12/2006 | US20060008446 Delivering antiinflammatory cytokines to nervous system using gene therapy techniques |
| 01/12/2006 | CA2571598A1 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/11/2006 | EP1614680A2 Process for preparing 2-iminopyrrolidine derivatives |
| 01/11/2006 | EP1614426A1 Attenuated strains of vibrio cholerae and lyophilised vaccines containing same |
| 01/11/2006 | EP1614421A2 Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| 01/11/2006 | EP1613616A2 Process for making substituted pyrazoles |
| 01/11/2006 | EP1613614A2 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| 01/11/2006 | EP1613595A2 Novel compounds and compositions as protein kinase inhibitors |
| 01/11/2006 | EP1613592A2 Hydroxamic acid compounds and methods of use thereof |
| 01/11/2006 | EP1613585A2 Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase |
| 01/11/2006 | EP1613369A2 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
| 01/11/2006 | EP1613368A2 Carboxamide spirohydantoin cgrp receptor antagonists |
| 01/11/2006 | EP1613352A2 Micro-cluster compositions |
| 01/11/2006 | EP1613347A2 Humanized antibodies that recognize beta amyloid peptide |
| 01/11/2006 | EP1613345A2 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 |
| 01/11/2006 | EP1613344A2 Anti-tumor vasculature effects of human serum albumin derivatives |
| 01/11/2006 | EP1613340A2 Treatment of aspergillus infections with thymosin alpha 1 |
| 01/11/2006 | EP1613338A2 Tamandarin analogs and fragments thereof and methods of making and using |
| 01/11/2006 | EP1613329A1 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| 01/11/2006 | EP1613311A2 Hif-1 inhibitors |
| 01/11/2006 | EP1613307A2 M sb 3 /sb muscarinic acetylcholine receptor antagonists |
| 01/11/2006 | EP1613305A1 Crystalline n-formyl hydroxylamine compounds |
| 01/11/2006 | EP1613300A2 Photostabilized topical formulations of ketoprofen containing two uv filters |
| 01/11/2006 | EP1613274A2 Conjugates comprising human il-18 and substitution mutants thereof |